Case Report: Stereotactic centralized ablative radiation therapy followed by hypofractionated radiotherapy is feasible for rapid local tumor debulking in bulky symptomatic metastatic non-small cell lung cancer

Background Bulky, symptomatic tumors can compromise performance and nutritional status and may limit the immediate feasibility of systemic anticancer therapy. Stereotactic centralized ablative radiation therapy (SCART) enables focal delivery of ablative doses within larger tumor volumes with reduced doses in surrounding normal tissues. However, clinical experience with SCART followed by hypofractionated radiotherapy (HFRT) for rapid debulking of bulky symptomatic metastatic tumors remains limited, particularly in patients with temporarily limited treatment options. This case report describes the feasibility and clinical course of SCART followed by HFRT in a patient with bulky symptomatic metastatic non-small cell lung cancer (NSCLC). Case presentation A 67-year-old man with metastatic squamous NSCLC presented with a rapidly enlarging sternal metastasis 100 mm in maximum diameter, severe pain, dyspnea, and difficulty eating. His Karnofsky performance status (KPS) score was 70, accompanied by marked anemia, hypoalbuminemia, and high nutritional risk. Because the patient initially declined systemic anticancer therapy, SCART was administered to the sternal metastasis (36 Gy in 3 fractions), followed by HFRT (45 Gy in 15 fractions). The primary lung tumor was treated concurrently with HFRT (30 Gy in 10 fractions). Three weeks after radiotherapy, the maximum diameters of the sternal metastasis and primary tumor had decreased from 100 and 67 mm to 46 and 40 mm, respectively, with concomitant alleviation of symptoms. The patient subsequently received systemic therapy with paclitaxel, carboplatin, and penpulimab. No grade ≥3 acute radiation-related toxicity was observed during follow-up. Conclusion In this patient, SCART followed by HFRT, together with nutritional support, was associated with rapid local tumor regression and symptomatic improvement, facilitating the subsequent initiation of systemic anticancer therapy. Although the independent contribution of SCART cannot be determined from this single case, rapid local tumor debulking may create opportunities for subsequent systemic therapy in selected patients with bulky symptomatic metastatic disease and temporarily limited treatment options. Nevertheless, the short follow-up precludes conclusions regarding durable local control, late toxicity, and long-term quality-of-life improvement. Further studies are warranted to evaluate the efficacy and safety of this sequential treatment strategy.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1991309
Primary Topic
Lung Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Stereotactic centralized ablative radiation therapy followed by hypofractionated radiotherapy is feasible for rapid local tumor debulking in bulky symptomatic metastatic non-small cell lung cancer

Lei Zhou, Shiyun Xing, Jiandong Fu, Hu Ma et al.
1 links
Frontiers in Oncology
Lung Cancer Diagnosis and Treatment
article

Case Report: Stereotactic centralized ablative radiation therapy followed by hypofractionated radiotherapy is feasible for rapid local tumor debulking in bulky symptomatic metastatic non-small cell lung cancer

Lei Zhou, Shiyun Xing, Jiandong Fu, Hu Ma, Yu Zhang, Wenwen Zhang
article en

Abstract

Background Bulky, symptomatic tumors can compromise performance and nutritional status and may limit the immediate feasibility of systemic anticancer therapy. Stereotactic centralized ablative radiation therapy (SCART) enables focal delivery of ablative doses within larger tumor volumes with reduced doses in surrounding normal tissues. However, clinical experience with SCART followed by hypofractionated radiotherapy (HFRT) for rapid debulking of bulky symptomatic metastatic tumors remains limited, particularly in patients with temporarily limited treatment options. This case report describes the feasibility and clinical course of SCART followed by HFRT in a patient with bulky symptomatic metastatic non-small cell lung cancer (NSCLC). Case presentation A 67-year-old man with metastatic squamous NSCLC presented with a rapidly enlarging sternal metastasis 100 mm in maximum diameter, severe pain, dyspnea, and difficulty eating. His Karnofsky performance status (KPS) score was 70, accompanied by marked anemia, hypoalbuminemia, and high nutritional risk. Because the patient initially declined systemic anticancer therapy, SCART was administered to the sternal metastasis (36 Gy in 3 fractions), followed by HFRT (45 Gy in 15 fractions). The primary lung tumor was treated concurrently with HFRT (30 Gy in 10 fractions). Three weeks after radiotherapy, the maximum diameters of the sternal metastasis and primary tumor had decreased from 100 and 67 mm to 46 and 40 mm, respectively, with concomitant alleviation of symptoms. The patient subsequently received systemic therapy with paclitaxel, carboplatin, and penpulimab. No grade ≥3 acute radiation-related toxicity was observed during follow-up. Conclusion In this patient, SCART followed by HFRT, together with nutritional support, was associated with rapid local tumor regression and symptomatic improvement, facilitating the subsequent initiation of systemic anticancer therapy. Although the independent contribution of SCART cannot be determined from this single case, rapid local tumor debulking may create opportunities for subsequent systemic therapy in selected patients with bulky symptomatic metastatic disease and temporarily limited treatment options. Nevertheless, the short follow-up precludes conclusions regarding durable local control, late toxicity, and long-term quality-of-life improvement. Further studies are warranted to evaluate the efficacy and safety of this sequential treatment strategy.

Frontiers in OncologyVol. 16
Zunyi Medical University (CN)
Good health and well-being
Lung Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon